ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Preliminary NICE ‘no’ for Takeda’s Alunbrig
October 11, 2018Draft guidelines from the National Institute for Health and Care Excellence do not recommend NHS funding for Takeda’s lung cancer drug Alunbrig. -
Takeda’s Alunbrig shows promise as first-line ALK NSCLC therapy
September 27, 2018Takeda’s Alunbrig cut the risk of disease progression or death by more than 50% compared to Pfizer’s Xalkori in adults with ALK+ non-small cell lung cancer. -
Takeda’s Alunbrig beats Pfizer’s Xalkori on PFS in ALK positive NSCLC
July 27, 2018Takeda’s Alunbrig has beaten Pfizer's Xalkori on progression-free survival (PFS) in a Phase III trial testing its efficacy as a front-line treatment for ALK-positive lung cancer.
Pharma Sources Insight January 2025
